The field of cardiovascular primary prevention has truly taken on global proportions and grows everyday with mounting interest from patients, physicians, insurers, national and international health agencies, and governments world wide. This enthusiasm for research on primary preven tion is encouraging; however, studies should be designed and interpreted with their broad context-including the economics of healthcare-in mind. JUPITER (Ridker PM et al. [2008] N Engl J Med 359: 2195-2207) serves as a good example of the new wave of cardio vascular prevention trials from which many lessons can be learnt.
JUPITER was a large, multinational, 4year, doubleblind, placebocontrolled, rando mized clinical trial that included 17,802 appar ently healthy men and women assigned to rosuva statin 20 mg or placebo. The study was designed to assess whether statin therapy should be given to individuals with normal levels of LDL cholesterol (<130 mg/dl), but ele vated levels of Creactive protein (CRP; >2.0 mg/l). In patients assigned to rosuva statin, LDLcholesterol and CRP levels were halved, and tri glyceride levels were reduced by 17% after 12 months of treatment. After 1.9 years of followup, treatment with rosuvastatin signifi cantly reduced the primary composite end point by 44%, as well as nearly all of the indivi dual end points-including a 55% reduction in nonfatal myocardial infarction, a 48% reduc tion in the risk of nonfatal stroke, and a 47% reduction in the risk of hard cardiac events (a compo site of myocardial infarction, stroke, and death from cardiovascular causes)-compared with placebo. The trial was halted by the Data and Safety Monitoring Board.
Although JUPITER clearly establishes the effi cacy of rosuvastatin for the reduction of cardio vascular events, it leaves us with a host of unanswered clinical and mechanistic questions.
The longterm safety of aggressive lipid lower ing, and the questionable increase in the inci dence of physicianreported diabetes in the rosuvastatin arm (3% versus 2.4%, number needed to harm [NNH] = 166), are left in doubt. Furthermore, although the study demonstrated high relativerisk reductions, the overall inci dence of the composite primary end point was only 2.8% in the placebo arm, with an absolute risk reduction of 1.2% (NNH = 83), and the inci dence of hard cardiovascular end points was only 1.8%, with an absolute risk reduction of 0.9% (NNH = 120).
Finally, almost 90,000 individuals were screened to establish the study population that the investigators perhaps inaccurately labeled as lowrisk, since almost half of the participants had a Framingham risk score of 10% or higher, and 41% of participants had the metabolic syndrome. To define the utility of highsensitivity (hs) CRP measurement as a strategy for identi fying individuals for treat ment would require a study where traditional risk factors guide manage ment in one arm, and hsCRP levels would guide management in the other. Issues that impact on the cost to the healthcare system-including requirement for large screening programs, relatively low yields, expensive drugs, etc.-are very important con siderations when evaluating the impact that any trial should have on treatment strategies.
JUPITER falls into the category of lipid lowering primary prevention studies, and estab lishes the paradigm of 'the lower the LDLcholesterol level the better', a maxim that already existed for secondary cardiovascular prevention. Nevertheless, JUPITER is a true landmark in preventive cardiology, not only for its findings, which will certainly affect primary prevention lipid guidelines, but even more so for the challenges it raises to our current strategies for risk assessment. 
JUPITER strikes earth

